You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
商業化確定性十足的18A,維昇藥業同類最佳隆培生長素預計2025年獲批商業化
格隆匯 10-02 11:54

國內長效生長激素市場在經歷了十年的沉寂,終於迎來重磅選手。

維昇藥業,攜其國內潛在同類最佳的長效生長激素——隆培促生長素,已向港交所提交上市申請。

隆培促生長素能夠在有限的治療週期內,通過長效給藥方式,顯著提高治療效果,確保患者達到最佳生長目標。作為同類首個在美國和歐盟獲批用於治療兒童生長激素缺乏症的長效生長激素,隆培促生長素在國內III期關鍵性試驗中更是展現出優於每日注射短效生長激素的療效和同等安全性,是一款潛在同類最佳的長效生長激素。

目前,隆培生長素在國內的上市申請已獲NMPA受理,預計將於2025年獲批上市,改變當前國內僅有一款長效生長激素的市場格局。

市場趨勢方面,中國生長激素市場滲透率遠低於歐美國家的10%以上,仍存在很大提升空間。隨着對兒童矮小症認識的提高和醫療技術的進步,《2024-2029年中國生長激素行業運營態勢與投資前景調查研究報吿》預計未來5至10年,中國生長激素滲透率將顯著提升至約10%,增長潛力巨大。

維昇藥業憑藉隆培促生長素的優勢,或能夠在這一增長趨勢中佔據領先地位,展現出較強的市場確定性和成長潛力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account